Telmisartan loaded nanofibers enhance re-endothelialization and inhibit neointimal hyperplasia

Chen Hung Lee*, Kuo Sheng Liu, Julien George Roth, Kuo Chun Hung, Yen Wei Liu, Shin Huei Wang, Chi Ching Kuo*, Shih Jung Liu*

*Corresponding author for this work

Research output: Contribution to journalJournal Article peer-review

6 Scopus citations

Abstract

Stent implantation impairs local endothelial function and may be associated with subsequent adverse cardiovascular events. Telmisartan, an angiotensin II receptor blocker that has unique peroxisome proliferator-activated-receptor-gamma-mediated effects on cardiovascular disease, has been shown to enhance endothelial function and limit neointimal hyperplasia. This study utilized hybrid biodegradable/stent nanofibers to facilitate sustained and local delivery of telmisartan to injured arterial vessels. Telmisartan and poly(D,L)-lactide-co-glycolide (PLGA) (75:25) were dissolved in hexafluoroisopropyl alcohol and electrospun into biodegradable nanofibrous tubes which were coated onto metal stents. By releasing 20% of the loaded telmisartan in 30 days, these hybrid biodegradable/stent telmisartan-loaded nanofibers increased the migration of endothelial progenitor cells in vitro, promoted endothelialization, and reduced intimal hyperplasia. As such, this work provides insights into the use of PLGA nanofibers for treating patients with an increased risk of stent restenosis.

Original languageEnglish
Article number1756
JournalPharmaceutics
Volume13
Issue number11
DOIs
StatePublished - 11 2021

Bibliographical note

Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.

Keywords

  • Controlled release
  • Drug-loaded nanofibers
  • PLGA
  • Telmisartan

Fingerprint

Dive into the research topics of 'Telmisartan loaded nanofibers enhance re-endothelialization and inhibit neointimal hyperplasia'. Together they form a unique fingerprint.

Cite this